

# ANNUAL HEALTH INSURANCE TREATMENT COST OF UNSPECIFIED FEMALE INFERTILITY BASED ON REAL-WORLD HEALTH INSURANCE CLAIMS DATA

**Kovács D<sup>2,3</sup>, Endrei D<sup>2</sup>, Csákvári T<sup>1</sup>, Elmer D<sup>2</sup>, Kajos LF<sup>2,3</sup>, Pónusz R<sup>2</sup>, Molics B<sup>2</sup>, Boncz I<sup>2</sup>.**

1.University of Pécs, Zalaegerszeg, Hungary, 2. University of Pécs, Pécs, Hungary, Doctoral School of Health Sciences, Faculty of Health Sciences, 3.University of Pécs, Pécs, Hungary

## OBJECTIVES

Female infertility is a global medical condition that could be caused by various disorders of the reproductive system. Female infertility constitutes a significant and growing burden on patients, health care systems and the society. Our aim was to determine the annual costs of the health insurance system related to the female infertility, n.o.s. in Hungary.

## METHODS

Data were derived from the financial database of the National Health Insurance Fund Administration of Hungary, of the year 2019. Data analyzed included annual health insurance costs, patient numbers and cost distribution calculated for age groups. The following cost categories were included into the study: general practice care, home care, in- and outpatient care, medical imaging, laboratory diagnostics, pharmaceuticals and medical aids. Patients with female infertility, n.o.s. were identified with the following code of the International Classification of Diseases 10th revision: N9790.

## RESULTS

In 2019, the Hungarian National Health Insurance Fund Administration spent 5.138 billion Hungarian Forints (HUF) on the treatment of patients with female infertility, 17.68 million American Dollars (USD), or 15.79 million Euros (EUR). The highest patient numbers were in outpatient care (26,160 women). Inpatient care (53.0% of total health insurance costs) utilization of pharmaceuticals (40.6%) and outpatient care (3.2%) were the main cost drivers, while all other forms of medical care amounted to 3.2% in women. Annual health care treatment cost per patient was 196,384 HUF (676USD/604 EUR) according to number of patients related to outpatient care. The highest annual health insurance costs were found in the '30-39' and '40-49' age groups.

## CONCLUSIONS

The utilization of inpatient care was the major cost driver, which was 1.39 times higher than use of pharmaceuticals, 16.56 times as much as outpatient care costs in 2019. The proportion of the costs of the treatment showed a significant difference among age groups.

DENOMINATION OF THE TYPE OF THE TREATMENT	NUMBER OF PATIENTS	NUMBER OF CASES	ANNUAL EXPENDITURE IN HUF
GENERAL PRACTITIONER OUTPATIENT CARE	9,860	30,693	61,616,586 Ft
CHRONIC INPATIENT CARE	85	85	19,958,400 Ft
LABORATORY DIAGNOSTICS	12,797	31,376	80,926,750 Ft
CT	59	79	3,317,415 Ft
INPATIENT CARE	7,467	9,890	2,720,533,741 Ft
PHARMACEUTICALS	15,914	111,015	2,086,708,465 Ft

Table 1. Annual utilization of infertility in accordance to the type of the treatment in 2019




Figure 1. Distribution of the annual expenditures in accordance to the type of the financed treatment




Figure 2. Distribution of the annual expenditure in accordance to the age groups of the study sample in 2019

**ISPOR 2022**  
May 15-18, 2022  
Washington, DC, USA Area and Virtual



**Funding:**  
The research was financed by the National Laboratory for Human Reproduction (HRNL) established under the leadership of the University of Pécs.

**Corresponding author:**  
Dalma Kovács, MS.c  
University of Pécs, Faculty of Health Sciences, Hungary  
Institute for Health Insurance  
E-mail: dalma.kovacs@etk.pte.hu

